(Q37918314)

25 August 2017

1 reference

title

Management of pain in multiple sclerosis: a pharmacological approach (English)

1 reference

25 August 2017

0 references

0 references

1 reference

Claudio Solaro

1

1 reference

25 August 2017

Michele Messmer Uccelli

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

16 August 2011

1 reference

25 August 2017

published in

Nature Reviews Neurology

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

519-527

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.120

25 August 2017

exact match

0 references

cites work

Symptomatic medication use in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Persistent pain and uncomfortable sensations in persons with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain in multiple sclerosis patients. A prospective study using the Mc Gill Pain Questionnaire

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain in chronic multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain syndromes in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Acute and chronic pain syndromes in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain and sensory complaints in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Chronic pain in a large community sample of persons with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain in Patients With Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

The prevalence of pain in multiple sclerosis: A multicenter cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Central pain in multiple sclerosis--prevalence and clinical characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

The scope and nature of pain in persons with multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain due to multiple sclerosis: analysis of the prevalence and economic burden in Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Lifetime and actual prevalence of pain and headache in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Illness and demographic correlates of chronic pain among a community-based sample of people with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Considerations in the treatment of relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Multiple sclerosis: side effects of interferon beta therapy and their management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain in multiple sclerosis: a clinical and instrumental approach.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Health problems and health-related quality of life in people with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Severity of chronic pain and its relationship to quality of life in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Sensory function and quality of life in patients with multiple sclerosis and pain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Symptom cluster as a predictor of physical activity in multiple sclerosis: preliminary evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Antidepressants for neuropathic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Carbamazepine in the treatment of neuralgia. Use of side effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Open label gabapentin treatment for pain in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Acute delirium in patients with multiple sclerosis treated with pregabalin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Role of health-related quality of life measures in the routine care of people with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Trigeminal neuralgia in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Trigeminal neuralgia: pathology and pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Central trigeminal involvement in multiple sclerosis using high-resolution MRI at 3 T

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Trigeminal neuralgia and pain related to multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Trigeminal neuralgia (tic douloureux): MR imaging assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Topiramate relieves refractory trigeminal neuralgia in MS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Topiramate relieves idiopathic and symptomatic trigeminal neuralgia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Paroxysmal facial pain in disseminated sclerosis treated by retrogasserian glycerol injection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Radiofrequency trigeminal rhizotomy in treatment of symptomatic non-neoplastic facial pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Gamma knife radiosurgery for treatment of trigeminal neuralgia in multiple sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Reappraisal of Lhermitte's sign in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Glossopharyngeal neuralgia and MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Pain associated with multiple sclerosis: systematic review and proposed classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Botulinum toxin treatment of painful tonic spasms in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Symptomatic treatment in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Headache and multiple sclerosis: a population-based case-control study in Catania, Sicily

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Multiple sclerosis and headache co-morbidity. A case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Headaches and multiple sclerosis: a clinical study and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Primary headache and multiple sclerosis: preliminary results of a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Diagnosis and management of headache in adults: summary of SIGN guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Headache and multiple sclerosis: clinical and therapeutic correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

A randomized clinical trial of a wellness intervention for women with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Mindfulness of movement as a coping strategy in multiple sclerosis. A pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Psychological aspects of neuropathic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Advances in clinical research methodology for pain clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Assessment and treatment of neuropathic cancer pain following WHO guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Neuropathic pain: redefinition and a grading system for clinical and research purposes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

A critical review of visual analogue scales in the measurement of clinical phenomena

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

The reliability and validity of pain interference measures in persons with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

The visual analogue scale: its use in pain measurement.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Validation and Reliability of the Neuropathic Pain Scale (NPS) in Multiple Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.120

Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b

31 March 2020

1 reference

12 December 2020

The pain experience of a multiple sclerosis population: a descriptive study

1 reference

12 December 2020

Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study

1 reference

12 December 2020

Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study

1 reference

12 December 2020

Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis

1 reference

12 December 2020

Recent developments in the assessment of quality of life in multiple sclerosis (MS).

1 reference

12 December 2020

Chronic and acute pain syndromes in patients with multiple sclerosis

1 reference

12 December 2020

The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy

1 reference

12 December 2020

Clinical presentation of a patient with multiple sclerosis and response to manual chiropractic adjustive therapies.

1 reference

12 December 2020

Management of spasticity in multiple sclerosis by intrathecal baclofen.

1 reference

12 December 2020

Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features.

1 reference

12 December 2020

Association between comorbidity and clinical characteristics of MS.

1 reference

12 December 2020

Effects of osteopathic manipulative treatment and concentric and eccentric maximal-effort exercise on women with multiple sclerosis: a pilot study

1 reference

12 December 2020

Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia

1 reference

12 December 2020

Worsening of symptoms of multiple sclerosis associated with carbamazepine

1 reference

12 December 2020

10.1038/NRNEUROL.2011.120

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1025109852

0 references

1 reference